Downregulation of erythroid differentiation regulator 1 as a novel marker of skin tumors
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Young Bok | - |
dc.contributor.author | Kim, Hee Jung | - |
dc.contributor.author | Jung, Hwa Young | - |
dc.contributor.author | Park, Yong Gyu | - |
dc.contributor.author | Kim, Si Yong | - |
dc.contributor.author | Cho, Baik Kee | - |
dc.contributor.author | Cho, Daeho | - |
dc.contributor.author | Park, Hyun Jeong | - |
dc.date.available | 2021-02-22T11:48:30Z | - |
dc.date.issued | 2014-06 | - |
dc.identifier.issn | 0011-9059 | - |
dc.identifier.issn | 1365-4632 | - |
dc.identifier.uri | https://scholarworks.sookmyung.ac.kr/handle/2020.sw.sookmyung/10879 | - |
dc.description.abstract | BackgroundErythroid differentiation regulator 1 is decreased in malignant melanoma. However, the expression of erythroid differentiation regulator 1 has not been reported in normal epidermis, vessel, nerve, dermal adnexae, and various skin tumors. MethodsTo investigate the expression of erythroid differentiation regulator 1 in normal skin and various skin tumors, immunohistochemical analysis of normal skin, epidermal tumors, sebaceous tumors, and eccrine tumors was performed. The image analysis was quantitatively performed using HistoQuant software. ResultsErythroid differentiation regulator 1 was strongly expressed in the nuclei of normal epidermis, sebaceous gland, eccrine gland, vessel, and nerve. Expression of erythroid differentiation regulator 1 was weak in seborrheic keratosis, sebaceous hyperplasia, and eccrine spiradenoma. Erythroid differentiation regulator 1 was rarely observed in malignant skin tumors, including squamous cell carcinoma, basal cell carcinoma, malignant melanoma, sebaceous carcinoma, and eccrine porocarcinoma. ConclusionsThe expression of erythroid differentiation regulator 1 was negatively correlated with the malignant potential in various skin tumors. The results support the role of erythroid differentiation regulator 1 in cutaneous carcinogenesis and indicate its potential as a novel marker of skin tumors. | - |
dc.format.extent | 8 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.title | Downregulation of erythroid differentiation regulator 1 as a novel marker of skin tumors | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1111/ijd.12057 | - |
dc.identifier.scopusid | 2-s2.0-84900796809 | - |
dc.identifier.wosid | 000335983800021 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF DERMATOLOGY, v.53, no.6, pp 723 - 730 | - |
dc.citation.title | INTERNATIONAL JOURNAL OF DERMATOLOGY | - |
dc.citation.volume | 53 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 723 | - |
dc.citation.endPage | 730 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Dermatology | - |
dc.relation.journalWebOfScienceCategory | Dermatology | - |
dc.subject.keywordPlus | SQUAMOUS-CELL CARCINOMA | - |
dc.subject.keywordPlus | PROTEIN EXPRESSION | - |
dc.subject.keywordPlus | KI-67 ANTIGEN | - |
dc.subject.keywordPlus | IMMUNOHISTOCHEMISTRY | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | P53 | - |
dc.subject.keywordPlus | INDUCTION | - |
dc.subject.keywordPlus | MELANOMA | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | EDR | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Sookmyung Women's University. Cheongpa-ro 47-gil 100 (Cheongpa-dong 2ga), Yongsan-gu, Seoul, 04310, Korea02-710-9127
Copyright©Sookmyung Women's University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.